Annual Recurring Revenue (“ARR”)⁽¹⁾ up 35% YoY to $96.1 millionTotal Revenue up 52% YoY to $31.4 millionAdjusted EBITDA⁽¹⁾ up 47% YoY to $7.4 million TORONTO, March 18, 2026 (GLOBE NEWSWIRE) — Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today it has filed its Consolidated Financial Statements and Management’s Discussion and Analysis report for the year ended December 31, 2025 with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedarplus.com. “2025 was a milestone year for VitalHub, surpassing $100 million in revenue. In the fourth quarter, we achieved 10% annual organic ARR⁽¹⁾ growth and 24% adjusted EBITDA as a percentage of revenue⁽¹⁾,” said Dan Matlow, CEO of VitalHub. “We made significant acquisitions and filled in gaps in our portfolio...

HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (the “Company” or “Itafos”) today reported its Q4 2025 and full year 2025 financial results and provided a corporate update. The Company’s financial statements and management’s discussion and analysis for the three months and year ended December 31, 2025 are available under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.itafos.com. All figures are in thousands of US Dollars except as otherwise noted. A recorded webcast of management’s commentary reviewing the Q4 2025 financial results and an update on the business will be available on the Company’s website on Monday, March 23, 2026 (see details below). CEO Commentary Chief Executive Officer David Delaney commented, “we are pleased to report another quarter and year of...

A supplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release. Financial Highlights  Q4 2025 HighlightsTotal revenues1 were $173 million, up 13% Year-on-Year (YoY) Adjusted EBITDA1 was $69 million with Gross Margin at 66% AVT05 was approved as a biosimilar to Simponi® in the UK and European Economic Area (EEA) AVT03 was approved as a biosimilar to Prolia® and Xgeva® in the EEA The EMA accepted for review a marketing application for AVT23, referencing Xolair® After the end of the quarter, Alvotech...

REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights  A supplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release. Q4 2025 HighlightsTotal revenues1 were $173 million, up 13% Year-on-Year (YoY) Adjusted EBITDA1 was $69 million with Gross Margin at 66% AVT05 was approved as a biosimilar to Simponi® in the UK and European Economic Area (EEA) AVT03 was approved as a biosimilar to Prolia® and Xgeva® in the...

Third-Party Processing Growth and Hedging Gains Drive Debt Reduction; Strong Sulphur Prices Support Increase in Reserve Value Not For Distribution to United States News Wire Services or Dissemination in United States CALGARY, Alberta, March 18, 2026 (GLOBE NEWSWIRE) — Cavvy Energy Ltd. (“Cavvy” or the “Company”) (TSX:CVVY) is pleased to announce the release of its fourth quarter and full year 2025 financial and operating results. The Company produced 23,904 boe/d and generated Net Operating Income1 (“NOI”) of $110.5 million during 2025. The Company produced 23,003 boe/d and generated NOI of $20.8 million during the fourth quarter of 2025 with an exit production rate of 24,569 boe/d. During the first quarter of 2026, Cavvy repaid US$27.0 million of long-term debt, resulting in an undrawn senior revolving facility (US$22.0 million...

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today announced corporate updates and financial results for the year ended December 31, 2025. “In 2025, we continued to advance MT-601, our lead Multi-Antigen...

Fourth quarter revenue more than doubles sequentially with improved margins; Company continues to expand its footprint across key sectors SUNNYVALE, Calif, March 18, 2026 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid-deployment networking solutions for IoT and broadband applications, today reported its financial results for the full year ended December 31, 2025, and provided business and corporate updates. Revenues for the fourth quarter of 2025 were approximately $1.4 million, representing an increase of 113% from $0.64 million in the third quarter of 2025. For the full year 2025, revenues were $3.7 million, compared to $7.8 million in the prior year. The decrease was primarily driven by two large deals in 2024 that did not...

Total revenue of $1,572 million for the fourth quarter and $4,379 million for the full-year. Rental Segment(1) revenue of $772 million for the fourth quarter, an increase of 35% year over year, and full-year revenue of $2,724 million, an increase of 34% year over year. Net income of $65 million for the fourth quarter and $40 million for the full-year. Adjusted Core EBITDA(2) of $559 million for the fourth quarter and $1,667 million for the full-year. Mature rental location(1) adjusted EBITDA margins were 54% for the full-year. Mature rental location(1) return on invested capital was 16.5% for the full year. 385 locations(4) with 95 new locations opened during the full-year.COLUMBIA, Mo., March 18, 2026 (GLOBE NEWSWIRE) — EquipmentShare.com Inc (Nasdaq: EQPT) (“EquipmentShare” or the “Company”) today reported financial results...

Q4 2025: Revenue increased 77% to $27.2 million, gross profit rose to $11.1 million, and gross margin expanded to 40.7% from 36.4% in the prior-year quarter. Q4 2025: Net income was $2.6 million and Adjusted EBITDA was $4.1 million, compared to a net loss of $6.8 million and Adjusted EBITDA loss of $1.1 million in the prior-year period. FY 2025: Revenue increased 26% to $71.9 million, gross profit rose 35% to $27.5 million, and gross margin improved to 38.3% from 35.9%. FY 2025: SUNation exceeded the top end of its prior revenue guidance, generated approximately $1.0 million of operating cash flow, and delivered $2.5 million of Adjusted EBITDA. FY 2025: SUNation materially strengthened its balance sheet, ending the year with approximately $7.2 million of liquidity and an estimated 57% reduction in total debt. New York and Hawaii drove...

CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com. Investor Relations Contact:Shai Biran, PhDSpero...